Trial · NCT04652726
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
NCT04652726, Phase 3, Completed, Novartis Pharmaceuticals; results first posted 2025-06-10
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia. Trials, record NCT04652726. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04652726
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
- NCT number
- NCT04652726
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 141 participants, actual
- Lead sponsor
- Novartis Pharmaceuticals
- Conditions
- Familial Hypercholesterolemia - Heterozygous
- Interventions
- Inclisiran, Placebo
- First posted
- 2020-12-03
- Last updated
- 2026-01-13
- Other registries' IDs
- eudract:2020-002757-18
- Results first posted
- 2025-06-10
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) | Baseline and Day 330 | Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 (Year 1) |
| Secondary | Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1) | Baseline, after Day 90 up to Day 330 | Time-adjusted percent change in LDL-C (after Day 90 and up to Day 330), calculated as the average of percent changes from baseline to Days 150, 270 and 330 |
| Secondary | Absolute Change in LDL-C From Baseline to up Day 330 (Part 1/Year 1) | Baseline and Day 330 | Absolute change in LDL-C from baseline to Day 330. |
| Secondary | Percent Change in Apo B From Baseline up to Day 330 (Part 1/Year 1) | Baseline and Day 330 | Percentage change in apolipoprotein B (Apo B) from baseline to Day 330. |
| Secondary | Percent Change in Lp(a) From Baseline up to Day 330 (Part 1/Year 1) | Baseline and Day 330 | Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to Day 330. |
| Secondary | Percent Change in Non-HDL-C From Baseline up to Day 330 (Part 1/Year 1) | Baseline and Day 330 | Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to Day 330. |
| Secondary | Percent Change in Total Cholesterol From Baseline up to Day 330 (Part 1/Year 1) | Baseline and Day 330 | Percentage change in total cholesterol from baseline to Day 330. |
| Secondary | Percent Change in LDL-C From Baseline up to Day 720 | Baseline, up to Day 720 | Percentage change in LDL-C from baseline to each assessment time up to Day 720. |
| Secondary | Absolute Change in LDL-C From Baseline up to Day 720 | Baseline, up to Day 720 | Absolute change in LDL-C from baseline to each assessment time up to Day 720. |
| Secondary | Percent Change in Apo B From Baseline up to Day 720 | Baseline, up to Day 720 | Percentage change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720. |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes27
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) | Baseline and Day 330 | Full Analysis Set (FAS) comprised all participants to whom study treatment had been assigned by randomization. | percent change in LDL-C | LEAST_SQUARES_MEAN |
| SECONDARY | Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1) | Baseline, after Day 90 up to Day 330 | Full Analysis Set (FAS) comprised all participants to whom study treatment had been assigned by randomization | Time-adjusted percent change in LDL-C | LEAST_SQUARES_MEAN |
| SECONDARY | Absolute Change in LDL-C From Baseline to up Day 330 (Part 1/Year 1) | Baseline and Day 330 | Full Analysis Set (FAS) comprised all participants to whom study treatment had been assigned by randomization | mg/dL | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change in Apo B From Baseline up to Day 330 (Part 1/Year 1) | Baseline and Day 330 | Full Analysis Set (FAS) comprised all participants to whom study treatment had been assigned by randomization | Percent change in Apo B | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change in Lp(a) From Baseline up to Day 330 (Part 1/Year 1) | Baseline and Day 330 | Full Analysis Set (FAS) comprised all participants to whom study treatment had been assigned by randomization | Percent change in Lp(a) | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change in Non-HDL-C From Baseline up to Day 330 (Part 1/Year 1) | Baseline and Day 330 | Full Analysis Set (FAS) comprised all participants to whom study treatment had been assigned by randomization | Percent change in non-HDL-C | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change in Total Cholesterol From Baseline up to Day 330 (Part 1/Year 1) | Baseline and Day 330 | Full Analysis Set (FAS) comprised all participants to whom study treatment had been assigned by randomization | Percent change in total cholesterol | LEAST_SQUARES_MEAN |
| SECONDARY | Percent Change in LDL-C From Baseline up to Day 720 | Baseline, up to Day 720 | Full Analysis Set (FAS) comprised all participants to whom study treatment had been assigned by randomization. At each time point, only subjects with a value at both baseline and that time point are included. | Percent change in LDL-C | MEAN |
| SECONDARY | Absolute Change in LDL-C From Baseline up to Day 720 | Baseline, up to Day 720 | Full Analysis Set (FAS) comprised all participants to whom study treatment had been assigned by randomization. At each time point, only subjects with a value at both baseline and that time point are included. | mg/dL | MEAN |
| SECONDARY | Percent Change in Apo B From Baseline up to Day 720 | Baseline, up to Day 720 | Full Analysis Set (FAS) comprised all participants to whom study treatment had been assigned by randomization. At each time point, only subjects with a value at both baseline and that time point are included. | Percent change in Apo B | MEAN |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 outcomesResults by group190
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) | Part 1- Inclisiran | -27.14 | 95% Confidence Interval -32.04 to -22.24 | percent change in LDL-C | |
| Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) | Part 1 - Placebo | 1.40 | 95% Confidence Interval -3.97 to 6.78 | percent change in LDL-C | |
| Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1) | Part 1- Inclisiran | -26.04 | 95% Confidence Interval -30.11 to -21.98 | Time-adjusted percent change in LDL-C | |
| Time-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1) | Part 1 - Placebo | 3.26 | 95% Confidence Interval -2.37 to 8.89 | Time-adjusted percent change in LDL-C | |
| Absolute Change in LDL-C From Baseline to up Day 330 (Part 1/Year 1) | Part 1- Inclisiran | -50.54 | 95% Confidence Interval -59.22 to -41.86 | mg/dL | |
| Absolute Change in LDL-C From Baseline to up Day 330 (Part 1/Year 1) | Part 1 - Placebo | -0.55 | 95% Confidence Interval -10.48 to 9.38 | mg/dL | |
| Percent Change in Apo B From Baseline up to Day 330 (Part 1/Year 1) | Part 1- Inclisiran | -21.46 | 95% Confidence Interval -25.59 to -17.33 | Percent change in Apo B | |
| Percent Change in Apo B From Baseline up to Day 330 (Part 1/Year 1) | Part 1 - Placebo | 4.24 | 95% Confidence Interval -0.07 to 8.56 | Percent change in Apo B | |
| Percent Change in Lp(a) From Baseline up to Day 330 (Part 1/Year 1) | Part 1- Inclisiran | -5.04 | 95% Confidence Interval -14.21 to 4.13 | Percent change in Lp(a) | |
| Percent Change in Lp(a) From Baseline up to Day 330 (Part 1/Year 1) | Part 1 - Placebo | 1.14 | 95% Confidence Interval -5.48 to 7.77 | Percent change in Lp(a) |
1 to 10 of 190Source ClinicalTrials.gov
See all 190 results by groupParticipant flow18
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1 (Double-blind Period) | STARTED | Part 1- Inclisiran | 93 | |
| Part 1 (Double-blind Period) | STARTED | Part 1 - Placebo | 48 | |
| Part 1 (Double-blind Period) | STARTED | Part 2 - Inclisiran (Total) | 0 | |
| Part 1 (Double-blind Period) | COMPLETED | Part 1- Inclisiran | 91 | |
| Part 1 (Double-blind Period) | COMPLETED | Part 1 - Placebo | 48 | |
| Part 1 (Double-blind Period) | COMPLETED | Part 2 - Inclisiran (Total) | 0 | |
| Part 1 (Double-blind Period) | NOT COMPLETED | Part 1- Inclisiran | 2 | |
| Part 1 (Double-blind Period) | NOT COMPLETED | Part 1 - Placebo | 0 | |
| Part 1 (Double-blind Period) | NOT COMPLETED | Part 2 - Inclisiran (Total) | 0 | |
| Part 2 (Open-label Period) | STARTED | Part 1- Inclisiran | 0 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 participant flowAdverse events81
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Part 1 - Inclisiran | 4 | 93 | |
| other | Nausea | Gastrointestinal disorders | Part 1 - Placebo | 1 | 48 | |
| other | Nausea | Gastrointestinal disorders | Part 2 - Inclisiran (Total) | 4 | 139 | |
| other | Vomiting | Gastrointestinal disorders | Part 1 - Inclisiran | 5 | 93 | |
| other | Vomiting | Gastrointestinal disorders | Part 1 - Placebo | 1 | 48 | |
| other | Vomiting | Gastrointestinal disorders | Part 2 - Inclisiran (Total) | 0 | 139 | |
| other | Fatigue | General disorders | Part 1 - Inclisiran | 4 | 93 | |
| other | Fatigue | General disorders | Part 1 - Placebo | 1 | 48 | |
| other | Fatigue | General disorders | Part 2 - Inclisiran (Total) | 0 | 139 | |
| other | Influenza like illness | General disorders | Part 1 - Inclisiran | 4 | 93 |
1 to 10 of 81Source ClinicalTrials.gov
See all 81 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Part 1 - Inclisiran | 0 | 93 |
| Total, all-cause mortality | Part 1 - Placebo | 0 | 48 |
| Total, all-cause mortality | Part 2 - Inclisiran (Total) | 0 | 139 |
| Total, other adverse events | Part 1 - Inclisiran | 57 | 93 |
| Total, other adverse events | Part 1 - Placebo | 29 | 48 |
| Total, other adverse events | Part 2 - Inclisiran (Total) | 52 | 139 |
| Total, serious adverse events | Part 1 - Inclisiran | 3 | 93 |
| Total, serious adverse events | Part 1 - Placebo | 1 | 48 |
| Total, serious adverse events | Part 2 - Inclisiran (Total) | 6 | 139 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04652726
GET https://conductscience.org/api/trials/v1/NCT04652726/registered?page=2